Target a better now with ImmunoGen, Inc., a biotechnology company focused on the development of antibody-drug conjugate (ADC) technology to treat cancer.
ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts. Wikipedia
People also ask
What is the purpose of the ImmunoGen?
What is going on with ImmunoGen?
Did ImmunoGen get acquired?
What is the history of ImmunoGen?
Nov 30, 2023 · AbbVie will acquire all outstanding ImmunoGen common stock for $31.26 per share in cash. The proposed transaction is subject to customary ...
ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer.
Feb 12, 2024 · AbbVie has acquired all outstanding ImmunoGen common stock for $31.26 per share. It is expected that ImmunoGen's common stock will cease to ...
Immunogen | IMGN Stock Price, Company Overview & News - Forbes
www.forbes.com › companies › immuno...
ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients.
ImmunoGen, Inc. is a commercial-stage biotechnology company. The Company is focused on developing and commercializing of antibody- drug conjugates (ADCs) to ...
We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics ...